Trial Profile
A Phase 1, Single Dose, Fixed Sequence, 2-Period Cross-Over Absolute Oral Bioavailability Study In Healthy Volunteers Comparing Oral To Intravenous Administration Of PD-0332991
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Palbociclib (Primary)
- Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Multiple myeloma; Solid tumours
- Focus Pharmacokinetics
- 30 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Apr 2013 Planned initiation date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.